Retrospective analysis reveals immune profile association with poor prognosis in salivary gland carcinomas, suggesting new biomarkers.
Salivary gland carcinomas (SGC) are rare and heterogeneous tumors with limited therapeutic options in advanced stages. Recent evidence suggests a potential role of the tumor immune microenvironment (TME) in disease progression. This study aimed to investigate the immune profile of SGCs by analyzing tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and PD-L1 expression, and to assess their correlation with histological grade and clinical outcome. A retrospective analysis was conducted on 103 SGC cases. Immunohistochemistry for CD3, CD4, CD8, CD20, CD56, PD-1, PD-L1, FOXP3, CD68, and CD163 was performed. Digital slide analysis was carried out in intratumoral and peritumoral regions using QuPath software. High intratumoral FOXP3 + Tregs were significantly associated with high-grade tumors and worse progression-free survival (PFS) (p = 0.009). A higher peritumoral CD3 + T cell density correlated with poor prognosis (p = 0.046). Concordance between pathologist assessments and QuPath quantification was moderate to high (Cohen’s K = 0.71). In conclusion, intratumoral Tregs and peritumoural T lymphocytes may be used as negative prognostic biomarkers. Future multicentric studies and AI (Artificial Intelligence)-driven analyses could enhance immune characterization and guide immunotherapeutic strategies in SGC.
No takes yet. Share an insight, caveat, or question.
Anconelli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: